News
Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
18don MSN
Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will ...
Hosted on MSN19d
Eli Lilly strikes $1.3bn gene therapy deal with RznomicsEli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback